These days, when it comes to drug development and market access, patients don’t just have a voice. With patients or patient representatives now having seats at tables that make pivotal decisions affecting your product’s commercial success (e.g. market approval, reimbursement), they have power.
For R&D teams, that means listening to patients from an early stage is crucial to avoid derailing clinical programs further down the road if patients’ needs are not met sufficiently.
Engagement with patients can also provide invaluable input into your drug development program, improve clinical trial design, and even help support market adoption. Providing insight into unmet needs to allow more patient-centric trial design, or enabling collection of real-world data for strengthening product approval and launch efforts can all massively increase chances of your program’s success.
Then there are the physicians that are associated with patient groups. They are most likely to have their fingers on the pulse of what patients experience in the clinic, and are therefore worthwhile engaging with for support with your program.
The question then isn’t really “should we reach out to patient groups?”, but “can we afford not to?”
With Thecosystems, you’ll have access to details of all the Alzheimer’s patient groups you need to know about - including the physicians associated with them - in whichever regions you’re interested in, in seconds.
When you change the way you look at things, the things you look at change
Let’s talk
Do you want any text here explaining what to expect?
.svg)
.png)
.svg)
.svg)
